0Y7T Allergan Plc

TIDM0Y7T

RNS Number : 0914E

UBS O'Connor Limited

25 February 2020

Ap19

   FORM   8.3 
   IRISH  TAKEOVER   PANEL 
   DISCLOSURE UNDER RULE 8.3 OF THE IRISH  TAKEOVER   PANEL ACT,  1997,  TAKEOVER  RULES, 2013 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

   1.       KEY   INFORMATION 
 
Name of person dealing           UBS O'Connor [i] 
 (Note 1) 
Company dealt in                   Allergan plc 
                            ========================== 
Class of relevant security   US$0.0001 Ordinary Shares 
 to which the dealings 
 being disclosed relate 
 (Note 2) 
                            ========================== 
Date of dealing                  24-February-2020 
                            ========================== 
 
   2.         INTERESTS AND SHORT POSITIONS 

(a) Interests and short positions (following dealing) in the class of relevant

security   dealt   in   (Note   3) 
 
                                         Long               Short 
                             Number      (%)     Number       (%) 
                             =========  ======  ===========  ====== 
(1) Relevant securities 
                             =================  =================== 
(2) Derivatives (other 
 than options)               4,345,239 1.32 
                             =================  =================== 
(3) Options and agreements 
 to purchase/sell 
                             =================  =================== 
Total                        4,345,239 1.32 
                             =================  =================== 
 
 

(b) Interests and short positions in relevant securities of the company, other than the class dealt

  in   (Note   3) 
 
Class of relevant security:                Long                Short 
                              Number        (%)     Number         (%) 
                              =========    ======  ===========    ====== 
(1) Relevant securities 
                              ===================  ===================== 
 
  (2) Derivatives (other 
  than options) 
                              ===================  ===================== 
 
  (3) Options and agreements 
  to purchase/sell 
                              ===================  ===================== 
Total 
                              ===================  ===================== 
 
 

Ap20

   1.       DEALINGS  (Note   4) 
   (a)      Purchases and sales 
 
 
  Purchase/sale           Number of relevant securities        Price per unit 
                                                               (Note 5) 
 
 
   (b)      Derivatives transactions (other than options transactions) 
 
Product    Nature of transaction  Number of relevant   Price per 
 name,      (Note 6)               securities           unit 
 e.g. CFD                          (Note 7)             (Note 5) 
   CFD           Purchase              100,000         198.0231 
                                                          USD 
           =====================  ==================  ========== 
 
   (c)      Options transactions in respect of existing relevant securities 
   (i)       Writing,  selling, purchasing or varying 
 
Product     Writing,      Number of       Exercise  Type,            Expiry  Option 
 name,       selling,      securities      price     e.g. American,   date    money paid/received 
 e.g. call   purchasing,   to which                  European                 per unit 
 option      varying       the option                etc.                     (Note 5) 
             etc.          relates (Note 
                           7) 
 
 
   (ii)      Exercising 
 
Product name,             Number of securities      Exercise price 
 e.g. call option                                    per unit (Note 
                                                     5) 
 
 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

 
Nature of transaction         Details      Price per unit 
 (Note 8)                                   (if applicable) 
                                            (Note 5) 
 
 

Ap21

   2.       OTHER  INFORMATION 

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or

  relating   to   the   voting   rights   or   future   acquisition   or   disposal   of   any 

relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

   Is a Supplemental Form 8 attached?  (Note   9)      NO 
 
Date of disclosure            25-February-2020 
Contact name                   James Mortimer 
                              ================ 
Telephone number               0207 901 5828 
                              ================ 
If a connected EFM, name 
 of offeree/offeror with 
 which connected 
                              ================ 
If a connected EFM, state 
 nature of connection (Note 
 10) 
                              ================ 
 
   [i]   This report is on behalf of the following entities 
   --      UBS O'Connor Limited 
   --      UBS O'Connor LLC 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ISEKKPBBQBKDQBB

(END) Dow Jones Newswires

February 25, 2020 10:25 ET (15:25 GMT)

Grafico Azioni Allergan (LSE:0Y7T)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni Allergan (LSE:0Y7T)
Storico
Da Apr 2023 a Apr 2024